T-helper Cell Type-1 Transcription Factor T-Bet Is Down-regulated in Type 1 Diabetes
Abstract
T cells have been identified as key players in the pathogenesis of type 1 diabetes. However, the exact role of T-cell subpopulations in this pathway is presently unknown. The purpose of this study was to assess the expression pattern of two lineage-specifying transcription factors GATA-3 and T-bet, which are important in T helper type 1 (Th1) and Th2 cell development, respectively. Gene expression analysis of peripheral blood mononuclear cells (PBMCs) was performed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Plasma levels of IFN-γ and IL-4 were also determined by ELISA. T-bet and IFN-γ gene expression was significantly lower in patients group compared with healthy controls (p<0.05). The expression of GATA-3 was relatively similar in patients and controls; however, IL-4 mRNAs were significantly increased in the PBMCs from patients as compared with normal controls (p<0.05). In addition, a marked increase in plasma IL-4 levels were observed in patient group compared with controls (p<0.001). To the contrary, IFN-γ protein levels were decreased in patients in comparison with controls (p<0.001). These data suggest additional implications of the role of Th1/Th2 imbalance for the immunopathogenesis of type 1 diabetes.
1. Taborsky GJ Jr, Ahrén B, Havel PJ. Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. Diabetes 1998; 47(7):995-1005.
2. Boitard C. Pancreatic islet autoimmunity. Presse Med 2012; 41:e636-50.
3. Boitard C. T-lymphocyte recognition of beta cells in type 1 diabetes: clinical perspectives. Diabetes Metab 2013;39(6):459-66.
4. Berry G, Waldner H. Accelerated type 1 diabetes induction in mice by adoptive transfer of diabetogenic CD4+ T cells. J Vis Exp 2013; 75:e50389.
5. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011; 91(1):79-118.
6. Soldevila G, Buscema M, Doshi M, James RF, Bottazzo GF, Pujol-Borrell R. Cytotoxic effect of IFN-gamma plus TNF-alpha on human islet cells. J Autoimmun 1991;4(2):291-306.
7. Rabinovitch A, Baquerizo H, Sumoski W. Cytotoxic effects of cytokines on islet beta-cells: evidence for involvement of eicosanoids. Endocrinology 1990;126(1):67-71.
8. Bach JF, Chatenoud L. A historical view from thirty eventful years of immunotherapy in autoimmune diabetes. Semin Immunol 2011; 23(3):174-81.
9. Zhang Y, Zhang Y, Gu W, Sun B. TH1/TH2 cell differentiation and molecular signals. Adv Exp Med Biol 2014; 841:15-44.
10. Hultgren B, Huang X, Dybdal N, Stewart TA. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes 1996; 45(6):812-7.
11. Karlsson Faresjö MG, Ludvigsson J. Diminished Th1-like response to autoantigens in children with a high risk of developing type 1 diabetes. Scand J Immunol 2005;61(2):173-9.
12. Walldén J, Honkanen J, Ilonen J, Ludvigsson J, Vaarala O. No evidence for activation of T(H)1 or T(H)17 pathways in unstimulated peripheral blood mononuclear cells from children with ȕ-cell autoimmunity or T1D. J Inflamm Res 2008; 1:11-7.
13. Csorba TR, Lyon AW, Hollenberg MD. Autoimmunity and the pathogenesis of type 1 diabetes. Crit Rev Clin Lab Sci 2010; 47(2):51-71.
14. Vanaki E, Ataei M, Sanati MH, Mansouri P, Mahmoudi M, Zarei F, et al. Expression patterns of Th1/Th2 transcription factors in patients with guttate psoriasis. Acta Microbiol Immunol Hung 2013; 60(2):163-74.
15. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014; 311(17):1778-86.
16. Halminen M, Simell O, Knip M, Ilonen J. Cytokine expression in unstimulated PBMC of children with type 1 diabetes and subjects positive for diabetes-associated autoantibodies. Scand J Immunol 2001; 53(5):510-3.
17. Marwaha AK, Tan S, Dutz JP. Targeting the IL-17/IFN-Ȗ axis as a potential new clinical therapy for type 1 diabetes. Clin Immunol 2014; 154(1):84-9.
18. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus.Diabetes Metab Rev 1998; 14(2):129-51.
19. Cetkovic-Cvrlje M, Gerling IC, Muir A, Atkinson MA, Elliott JF, Leiter EH. Retardation or acceleration of diabetes in NOD/Lt mice mediated by intrathymic administration of candidate beta-cell antigens. Diabetes 1997; 46(12):1975-82.
20. Kolb H. Benign versus destructive insulitis. Diabetes Metab Rev 1997; 13(3):139-46.
21. Mueller R, Krahl T, Sarvetnick N. Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 1996; 184(3):1093-9.
22. Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993;178(1):87-99.
23. Mueller R, Bradley LM, Krahl T, Sarvetnick N.Mechanism underlying counterregulation of autoimmune diabetes by IL-4. Immunity 1997; 7(3):411-8.
24. Russell MA, Morgan NG. The impact of anti-inflammatory cytokines on the pancreatic ȕ-cell. Islets.2014; 6(3):e950547.
25. Hancock WW, Polanski M, Zhang J, Blogg N, Weiner HL. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Am J Pathol 1995; 147(5):1193-9.
26. Suarez-Pinzon W, Rajotte RV, Mosmann TR Rabinovitch A. Both CD4+ and CD8+ T-cells in syngeneic islet grafts in NOD mice produce interferon-gamma during beta-cell destruction. Diabetes 1996; 45(10):1350-7.
27. Zheng XX, Steele AW, Hancock WW, Stevens AC, Nickerson PW, Roy-Chaudhury P, et al. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. J Immunol 1997; 158(9):4507-13.
28. Deckert T. The immunogenicity of new insulins. Diabetes 1985; (34 Suppl 2):94-6.
29. Schloot N, Eisenbarth GS. Isohormonal therapy of endocrine autoimmunity. Immunol Today 1995;16(6):289-94.
30. Song YH, Li Y, Maclaren NK. The nature of autoantigens targeted in autoimmune endocrine diseases. Immunol Today 1996; 17(5):232-8.
31. Schloot NC, Roep BO, Wegmann D, Yu L, Chase HP, Wang T, et al. Altered immune response to insulin in newly diagnosed compared to insulin-treated diabetic patients and healthy control subjects. Diabetologia 1997;40(5):564-72.
32. Chatzigeorgiou A, Harokopos V, Mylona-Karagianni C, Tsouvalas E, Aidinis V, Kamper EF. The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time. Ann Med 2010; 42(6):426-38.
33. Rydén A, Ludvigsson J, Fredrikson M, Faresjö M.General immune dampening is associated with disturbed metabolism at diagnosis of type 1 diabetes. Pediatr Res.2014; 75(1-1):45-50.
34. Planas R, Carrillo J, Sanchez A, de Villa MC, Nuñez F, Verdaguer J, et al. Gene expression profiles for the human pancreas and purified islets in type 1 diabetes: new findings at clinical onset and in long-standing diabetes. Clin Exp Immunol 2010; 159(1):23-44.
35. Akhtar I, Gold JP, Pan LY, Ferrara JL, Yang XD, Kim JI, et al. CD4+ beta islet cell-reactive T cell clones that suppress autoimmune diabetes in nonobese diabetic mice.J Exp Med 1995; 182(1):87-97.
36. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995;268(5214):1185-8.
37. Kis J, Engelmann P, Farkas K, Engelmann P, Farkas K, Jalahej H, et al. Reduced CD4+ subset and Th1 bias of the human iNKT cells in Type 1 diabetes mellitus. J Leukoc Biol 2007; 81(3):654-62.
38. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996; 85(3):291-7.
39. Ghazarian L, Simoni Y, Pingris K, Beaudoin L, Lehuen A. Regulatory role of NKT cells in the prevention of type 1 diabetes. Med Sci (Paris) 2013; 29(8-9):722-8.
40. Karumuthil-Melethil S, Sofi MH, Gudi R, Johnson BM, Perez N, Vasu C. TLR2- and Dectin 1-associated innate immune response modulates T-cell response to pancreatic ȕ-cell antigen and prevents type 1 diabetes. Diabetes2015; 64(4):1341-57.
| Files | ||
| Issue | Vol 15, No 5 (2016) | |
| Section | Original Article(s) | |
| Keywords | ||
| Autoimmunity Cytokine Type 1 diabetes T lymphocyte | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
